← Oncology Approval Tracker

FDA DECISION ·

Ziihera + chemotherapy

zanidatamab-hrii with fluoropyrimidine and platinum chemotherapy · Jazz Pharmaceuticals

FDA approvalNew or expanded indicationGastroesophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for adults with unresectable locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma with HER2 IHC 3+ on an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

This regimen uses a narrower HER2 threshold than the tislelizumab combination. The FDA review attributed the progression-free survival effect primarily to the IHC 3+ subgroup.

What research teams should watch

Keep the IHC 3+ cutoff visible in order sets and eligibility review. When reporting the data, separate the chemotherapy-only combination arm from the tislelizumab-containing arm.

PRIMARY RECORDS

Sources